Zobrazeno 1 - 10
of 362
pro vyhledávání: '"M Meola"'
Autor:
Vicky K. Yang, Nicole Moyer, Runzi Zhou, Sally Z. Carnevale, Dawn M. Meola, Sally R. Robinson, Guoping Li, Saumya Das
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 3, p 1468 (2024)
Mitral valve prolapse (MVP) is a common valvular disease, affecting 2–3% of the adult human population and is a degenerative condition. A total of 5–10% of the afflicted will develop severe mitral regurgitation, cardiac dysfunction, congestive he
Externí odkaz:
https://doaj.org/article/e4522c5e387e4fc2a8c3f1a72ec63b5a
Autor:
Asma Boukhalfa, Sally R Robinson, Dawn M Meola, Nicholas A Robinson, Lauren A Ling, Joey N LaMastro, Jenica N Upshaw, Lakshmi Pulakat, Iris Z Jaffe, Cheryl A London, Howard H Chen, Vicky K Yang
Publikováno v:
PLoS ONE, Vol 18, Iss 3, p e0282859 (2023)
Chemotherapy-induced impairment of autophagy is implicated in cardiac toxicity induced by anti-cancer drugs. Imperfect translation from rodent models and lack of in vitro models of toxicity has limited investigation of autophagic flux dysregulation,
Externí odkaz:
https://doaj.org/article/5ea7be9f4e1b4e42ab80d1fbc2e93b4d
Autor:
Amelie Beaumier, Sally R. Robinson, Nicholas Robinson, Katherine E. Lopez, Dawn M. Meola, Lisa G. Barber, Barret J. Bulmer, Jerome Calvalido, John E. Rush, Ashish Yeri, Saumya Das, Vicky K. Yang
Publikováno v:
Journal of Veterinary Internal Medicine, Vol 34, Iss 3, Pp 1260-1271 (2020)
Abstract Background Long‐term use of doxorubicin (DOX) is limited by cumulative dose‐dependent cardiotoxicity. Objectives Identify plasma extracellular vesicle (EV)‐associated microRNAs (miRNAs) as a biomarker for cardiotoxicity in dogs by corr
Externí odkaz:
https://doaj.org/article/4df80e587dfd4da9846d67fd6b5ab77f
Autor:
A Marrese, M Meola, C Fonderico, A Salucci, G Comparone, V Pergola, D Faccenda, L Addeo, L Cocchiara, G Ammirati, A Rapacciuolo, T Strisciuglio
Publikováno v:
Europace. 25
Funding Acknowledgements Type of funding sources: None. Background Patients with atrial fibrillation (AF) have higher risk of ischemic stroke. Purpose We investigated whether AF patients experiencing an ischemic stroke have worse outcomes. Methods AF
Autor:
C Fonderico, D Faccenda, V Pergola, A Marrese, G Comparone, M Meola, A Salucci, L Cocchiara, L Addeo, G Ammirati, A Rapacciuolo, T Strisciuglio
Publikováno v:
Europace. 25
Funding Acknowledgements Type of funding sources: None. Background Heart failure with reduced ejection fraction (HFrEF) is associated in about one third of patients with abnormal conduction of the cardiac electrical impulse, resulting in asynchronous
Publikováno v:
American Journal of Veterinary Research. :1-11
OBJECTIVETo compare concentrations of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in aqueous humor from ophthalmologically normal dogs and dogs with naturally occurring primary angle-closure glaucoma (cPACG).S
Publikováno v:
Giornale di Clinica Nefrologia e Dialisi, Vol 21, Iss 1 (2018)
Abstract non disponibile
Externí odkaz:
https://doaj.org/article/9fd18f8cec424f66805e73f3f216f564
Autor:
Vicky K Yang, Albert K Tai, Terry P Huh, Dawn M Meola, Christine M Juhr, Nicholas A Robinson, Andrew M Hoffman
Publikováno v:
PLoS ONE, Vol 13, Iss 1, p e0188617 (2018)
Canine myxomatous mitral valve disease (MMVD) resembles the early stages of myxomatous pathology seen in human non-syndromic mitral valve prolapse, a common valvular heart disease in the adult human population. Canine MMVD is seen in older subjects,
Externí odkaz:
https://doaj.org/article/aa05f6cf70404993a91e7521cacd714b
Autor:
Vicky K. Yang, Kerry A. Loughran, Dawn M. Meola, Christine M. Juhr, Kristen E. Thane, Airiel M. Davis, Andrew M. Hoffman
Publikováno v:
Journal of Extracellular Vesicles, Vol 6, Iss 1 (2017)
Myxomatous mitral valve disease (MMVD) is functionally and histologically identical to mitral valve prolapse (MVP) in humans. Currently, there are no medical treatments that can delay the progression of this valvular disease or associated cardiac rem
Externí odkaz:
https://doaj.org/article/337460950a5348159089b2447b7d4a12
Publikováno v:
Am J Vet Res
OBJECTIVE To evaluate whether mesenchymal stem cells (MSCs) can be safely administered IV to dogs with congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD) to improve cardiac function and prolong survival time. ANIMALS 1